FDA approves first Stelara biosimilar, Wezlana
European Pharmaceutical Review
NOVEMBER 2, 2023
The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). US sales of Stelara totalled $6.4 The post FDA approves first Stelara biosimilar, Wezlana appeared first on European Pharmaceutical Review.
Let's personalize your content